A Phase I Study of HyperAcute-Renal (HAR) Immunotherapy In Patients With Metastatic Renal Cell Cancer

Trial Profile

A Phase I Study of HyperAcute-Renal (HAR) Immunotherapy In Patients With Metastatic Renal Cell Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Renal cancer vaccine-NewLink Genetics (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
    • 20 Sep 2016 Planned number of patients changed from 20 to 18.
    • 20 Sep 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top